According to articles published in highly respected journals such as "The Lancet" (395,507-513, 2020), it appears that 83% of COVID-19 patients suffer from fever, 82% from cough, 31% from breathing difficulties, and only 9% from mucus and 8% from sore throat. Therefore, there is great importance to quantify and detect the development of lung disease, which causes difficulty in breathing and coughing, without any signs of mucus and sore throat.
Technology which can monitor low frequencies can better monitor respiratory effort and detect the development of lung disease. Such technology can be used both to continuously monitor patients and to optimize treatment. I have no doubt that there is a powerful tool here that can be very helpful in managing the pandemic.
Prof. Amir Landsberg, MD, PhD
Faculty of Biomedical Engineering – Technion, Israel